Levi & Korsinsky notifies investors that it has commenced an investigation into Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) concerning potential violations of the federal securities laws.
On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. This outcome comes as a surprise to investors, given the company's previous optimism surrounding the drug’s potential. Following this news, shares of Supernus Pharmaceuticals fell over 13% in trading.
If you suffered a loss on your Supernus Pharmaceuticals, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





